UY26166A1 - Suspensión de ziprasidona - Google Patents

Suspensión de ziprasidona

Info

Publication number
UY26166A1
UY26166A1 UY26166A UY26166A UY26166A1 UY 26166 A1 UY26166 A1 UY 26166A1 UY 26166 A UY26166 A UY 26166A UY 26166 A UY26166 A UY 26166A UY 26166 A1 UY26166 A1 UY 26166A1
Authority
UY
Uruguay
Prior art keywords
ziprasidone
suspension
resuspend
polysorbate
wet
Prior art date
Application number
UY26166A
Other languages
English (en)
Inventor
Daniel Ray Arenson Y Hong Qi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY26166(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26166A1 publication Critical patent/UY26166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)

Abstract

Las composiciones que comprenden la base libre de ziprasidona o una sal de adición de ácidos de ziprasidona farmacéuticamente aceptable difícil de humectar, un polisorbato y dióxido de silicio coloidal forman buenas suspensiones acuosas que tienen una duración larga y son fáciles de resuspender si se produce sedimentación.
UY26166A 1999-05-27 2000-05-25 Suspensión de ziprasidona UY26166A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
UY26166A1 true UY26166A1 (es) 2000-12-29

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26166A UY26166A1 (es) 1999-05-27 2000-05-25 Suspensión de ziprasidona

Country Status (50)

Country Link
EP (1) EP1181018B1 (es)
JP (1) JP3942827B2 (es)
KR (1) KR100477782B1 (es)
CN (1) CN1196486C (es)
AP (1) AP1409A (es)
AR (1) AR022643A1 (es)
AT (1) ATE234097T1 (es)
AU (1) AU777413B2 (es)
BG (1) BG65367B1 (es)
BR (1) BR0010990A (es)
CA (1) CA2371550C (es)
CO (1) CO5170458A1 (es)
CR (1) CR6506A (es)
CU (1) CU23223B7 (es)
CZ (1) CZ20014230A3 (es)
DE (1) DE60001649T2 (es)
DK (1) DK1181018T3 (es)
DZ (1) DZ3049A1 (es)
EA (1) EA003907B1 (es)
EE (1) EE04704B1 (es)
ES (1) ES2191618T3 (es)
GC (1) GC0000190A (es)
GE (1) GEP20033113B (es)
GT (1) GT200000081A (es)
HK (1) HK1046366B (es)
HN (1) HN2000000071A (es)
HR (1) HRP20010878B1 (es)
HU (1) HUP0201297A3 (es)
IL (2) IL145950A0 (es)
IS (1) IS2396B (es)
MA (1) MA26741A1 (es)
MX (1) MXPA01012124A (es)
MY (1) MY127891A (es)
NO (1) NO320296B1 (es)
NZ (1) NZ514764A (es)
OA (1) OA11946A (es)
PA (1) PA8495801A1 (es)
PE (1) PE20010127A1 (es)
PL (1) PL196867B1 (es)
RS (1) RS50089B (es)
SI (1) SI1181018T1 (es)
SK (1) SK284590B6 (es)
SV (1) SV2001000085A (es)
TN (1) TNSN00112A1 (es)
TR (1) TR200103392T2 (es)
TW (1) TWI263498B (es)
UA (1) UA59491C2 (es)
UY (1) UY26166A1 (es)
WO (1) WO2000072847A1 (es)
ZA (1) ZA200109692B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
NZ529928A (en) 1999-10-29 2005-10-28 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
NZ534746A (en) * 2002-03-12 2006-06-30 Bristol Myers Squibb Co Palatable oral suspension and method
CN1703198A (zh) * 2002-10-25 2005-11-30 辉瑞产品公司 呈混悬剂形式的芳基杂环活性物质的贮库制剂
RU2310450C2 (ru) * 2002-10-25 2007-11-20 Пфайзер Продактс Инк. Новые депо-препараты для инъекций
EP1418492B1 (en) 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
EP1628973A2 (en) 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
WO2007052289A2 (en) 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
PA8495801A1 (es) 2001-12-14
AP2001002346A0 (en) 2001-12-31
PL352826A1 (en) 2003-09-08
IS2396B (is) 2008-08-15
IL145950A0 (en) 2002-07-25
SI1181018T1 (en) 2003-06-30
EE200100633A (et) 2003-02-17
OA11946A (en) 2006-04-13
CR6506A (es) 2004-03-24
BG106153A (bg) 2002-06-28
AU777413B2 (en) 2004-10-14
DK1181018T3 (da) 2003-04-22
TR200103392T2 (tr) 2002-11-21
HUP0201297A3 (en) 2005-09-28
YU76701A (sh) 2005-07-19
NO20015755L (no) 2002-01-23
EE04704B1 (et) 2006-10-16
JP2003500449A (ja) 2003-01-07
ZA200109692B (en) 2002-11-26
HK1046366A1 (en) 2003-01-10
EP1181018A1 (en) 2002-02-27
AP1409A (en) 2005-06-13
DE60001649T2 (de) 2003-08-21
TWI263498B (en) 2006-10-11
CA2371550A1 (en) 2000-12-07
IL145950A (en) 2007-12-03
SK284590B6 (sk) 2005-07-01
CN1196486C (zh) 2005-04-13
UA59491C2 (uk) 2003-09-15
HK1046366B (zh) 2005-07-29
PE20010127A1 (es) 2001-02-06
CA2371550C (en) 2007-01-02
DZ3049A1 (fr) 2004-03-27
NZ514764A (en) 2004-04-30
BR0010990A (pt) 2002-03-05
HUP0201297A2 (en) 2002-08-28
SK16782001A3 (sk) 2002-09-10
NO20015755D0 (no) 2001-11-26
KR20020048307A (ko) 2002-06-22
RS50089B (sr) 2009-01-22
MXPA01012124A (es) 2002-06-04
SV2001000085A (es) 2001-11-08
CU23223B7 (es) 2007-08-30
HN2000000071A (es) 2001-02-02
BG65367B1 (bg) 2008-04-30
IS6134A (is) 2001-10-30
CN1352560A (zh) 2002-06-05
CZ20014230A3 (cs) 2002-08-14
AR022643A1 (es) 2002-09-04
KR100477782B1 (ko) 2005-03-21
AU4138500A (en) 2000-12-18
NO320296B1 (no) 2005-11-21
EA200101131A1 (ru) 2002-04-25
ES2191618T3 (es) 2003-09-16
GT200000081A (es) 2001-11-16
WO2000072847A1 (en) 2000-12-07
EP1181018B1 (en) 2003-03-12
MA26741A1 (fr) 2004-12-20
MY127891A (en) 2006-12-29
CO5170458A1 (es) 2002-06-27
JP3942827B2 (ja) 2007-07-11
TNSN00112A1 (fr) 2005-11-10
ATE234097T1 (de) 2003-03-15
EA003907B1 (ru) 2003-10-30
HRP20010878B1 (en) 2007-03-31
GC0000190A (en) 2006-03-29
GEP20033113B (en) 2003-11-25
DE60001649D1 (de) 2003-04-17
HRP20010878A2 (en) 2003-06-30
PL196867B1 (pl) 2008-02-29

Similar Documents

Publication Publication Date Title
UY26166A1 (es) Suspensión de ziprasidona
DE50104135D1 (de) Wässrige zusammensetzungen
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO20013909D0 (no) Heteroaryl-substituerte kinolin-2-on derivater nyttige som anticancer midler
DE60218175D1 (de) Stabilisierte orale suspensionsformulierung
ATE289478T1 (de) Ektoparasitizide wässrige suspensionsformulierungen von spinosynen
PL357874A1 (en) Derivatives of quinoline as alpha-2 antagonists
MXPA03005505A (es) Compuesto modafinilo y mezclas de ciclodextrina.
DE60213132D1 (de) Puffer-torkran
DE60019993D1 (de) Wässrige Lysinlösungen
ECSP003496A (es) Suspensión de ziprasidona
DE60043591D1 (de) Aufzug
ATA17302000A (de) Aufzug
FR2804976B1 (fr) Sol amortissant pour aire d'activite
NO20025020D0 (no) Fremstilling av lavsvovelholdig destillater
NO20000177D0 (no) Opphengsanordning
FI20000024A0 (fi) Tuotenosturi/hissi/lifteri
IT251162Y1 (it) Pacchetto per sigarette
IT251166Y1 (it) Posacenere per pacchetto di sigarette
DK200000178U3 (da) Parallelophængt kopkost
SE9901549L (sv) Fällbar låda

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100521